LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
